Compare Stocks

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTR LadRx		$0.09	$0.05 ▼ $0.86	$4.14M	N/A	99,706 shs	4,000 shs
ENTX Entera Bio	$2.16 +5.4%	$1.60	$0.52 ▼ $3.35	$62.21M	1.7	210,482 shs	79,436 shs
NTGN Neon Therapeutics	$3.07	$3.03	$0.88 ▼ $6.25	$88.93M	-0.81	516,108 shs	N/A
OTLK Outlook Therapeutics	$8.29 +2.5%	$8.59	$4.00 ▼ $40.60	$107.85M	0.04	537,250 shs	120,803 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTR LadRx	0.00%	0.00%	0.00%	0.00%	0.00%
ENTX Entera Bio	+3.02%	-18.65%	+29.75%	+133.03%	+148.18%
NTGN Neon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
OTLK Outlook Therapeutics	-0.98%	-6.15%	-6.26%	-8.86%	-65.43%

This Apple-like Innovator is Revolutionizing Healthcare (Ad)

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	1.6111 of 5 stars	3.5	3.0	0.0	0.0	3.3	0.0	0.0
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	3.0677 of 5 stars	4.4	2.0	0.0	0.0	2.8	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTR LadRx	N/A	N/A	N/A	N/A
ENTX Entera Bio	3.00	Buy	$10.00	362.96% Upside
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	2.88	Moderate Buy	$46.43	460.01% Upside

Current Analyst Ratings

Latest OTLK, ENTX, CYTR, and NTGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2024	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/27/2024	OTLK Outlook Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
3/25/2024	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00
2/16/2024	OTLK Outlook Therapeutics	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
2/15/2024	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00
1/25/2024	OTLK Outlook Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$31.40
1/25/2024	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$40.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	$130K	478.52	N/A	N/A	$0.36 per share	6.00
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	$0.50 per share	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.11) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTR LadRx	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	-$8.89M	-$0.31	N/A	N/A	N/A	N/A	-101.78%	-83.90%	5/3/2024 (Estimated)
NTGN Neon Therapeutics	-$79.78M	-$2.86	N/A	N/A	N/A	N/A	-199.09%	-137.14%	N/A
OTLK Outlook Therapeutics	-$58.98M	-$4.00	N/A	N/A	N/A	N/A	-3,741.39%	-132.37%	5/20/2024 (Estimated)

Latest OTLK, ENTX, CYTR, and NTGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/8/2024	Q4 2023	ENTX Entera Bio	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A
2/14/2024	Q1 2024	OTLK Outlook Therapeutics	-$1.00	-$0.80	+$0.20	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTR LadRx	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTR LadRx	N/A	N/A	N/A
ENTX Entera Bio	N/A	10.32	10.32
NTGN Neon Therapeutics	0.43	1.58	3.00
OTLK Outlook Therapeutics	N/A	0.44	0.44

Ownership

Institutional Ownership

Company	Institutional Ownership
CYTR LadRx	N/A
ENTX Entera Bio	14.11%
NTGN Neon Therapeutics	54.71%
OTLK Outlook Therapeutics	11.20%

Insider Ownership

Company	Insider Ownership
CYTR LadRx	N/A
ENTX Entera Bio	8.90%
NTGN Neon Therapeutics	38.93%
OTLK Outlook Therapeutics	5.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTR LadRx	N/A	45.04 million	N/A	Not Optionable
ENTX Entera Bio	17	28.80 million	26.24 million	Optionable
NTGN Neon Therapeutics	102	28.97 million	N/A	Not Optionable
OTLK Outlook Therapeutics	24	13.01 million	12.32 million	Optionable

OTLK, ENTX, CYTR, and NTGN Headlines

Source	Headline
	Best's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positive finance.yahoo.com - April 22 at 1:21 PM
	USD/JPY Forecast: BoJ’s Rate Hike Talks and the Yen’s Outlook fxempire.com - April 22 at 1:21 PM
	WGA Releases New Housing Finance Outlook markets.businessinsider.com - April 22 at 1:21 PM
	Outlook Money’s Tushar Ghosh elevated to Publishing Director pitchonnet.com - April 22 at 1:21 PM
	Outlook: How to set up breaks between your meetings msn.com - April 22 at 1:21 PM
	Outlook Therapeutics, Inc. (OTLK) finance.yahoo.com - April 21 at 8:02 PM
	World Economic Outlook: IMF revises GDP predictions for LATAM and the Carribbean invezz.com - April 18 at 6:25 PM
	World Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and Prices finance.yahoo.com - April 18 at 6:25 PM
	Economic Outlook 2024 in Springfield connectionnewspapers.com - April 18 at 6:25 PM
	Bosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024 usnews.com - April 18 at 6:25 PM
	Reporter's Guarentee \| Outlook's Rakhi Bose In Conversation With Dalit Villagers In Saharanpur District outlookindia.com - April 18 at 6:25 PM
	Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million globenewswire.com - April 15 at 4:15 PM
	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential investorplace.com - April 15 at 12:54 PM
	Outlook Therapeutics (NASDAQ:OTLK) versus Vigil Neuroscience (NASDAQ:VIGL) Head-To-Head Contrast americanbankingnews.com - April 15 at 1:14 AM
	US Consumer Sentiment Falls Slightly as Outlook for Inflation Worsens msn.com - April 14 at 9:03 AM
	Microsoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot? msn.com - April 14 at 9:03 AM
	Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analysts americanbankingnews.com - April 13 at 4:32 AM
	Fed's Williams: Outlook is uncertain, Fed must be data-dependent fxstreet.com - April 11 at 6:05 PM
	National Gas’ Summer Outlook 2024: Stable supply, reduced exports energylivenews.com - April 11 at 6:05 PM
	ADB Outlook forecasts 7 % GDP growth in 2025 bbs.bt - April 11 at 6:05 PM
	Natural Gas Price Forecast: Moving Average Breakout Improves Bullish Outlook fxempire.com - April 11 at 1:44 AM
	Stock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate Cut msn.com - April 11 at 1:44 AM
	Bitdefender now has identity protection for Gmail and Outlook msn.com - April 11 at 1:44 AM
	Insiders are Piling into These 10 Healthcare Stocks in 2024 finance.yahoo.com - April 10 at 3:44 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

LadRx

NASDAQ:CYTR

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Entera Bio

NASDAQ:ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Neon Therapeutics

NASDAQ:NTGN

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Outlook Therapeutics

NASDAQ:OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial